Creatine for Cognitive Performance: The Case Nobody Talks About

Creatine has a branding problem. It sits in the sports nutrition section of every supplement store, next to protein powder and pre-workout, marketed to people trying to add muscle mass. The people who buy nootropics rarely consider it. The people who buy creatine rarely know it has cognitive evidence.

This is a mismatch worth correcting.

The cognitive case for creatine is based on a real mechanism, has more controlled human trial data than most compounds in the nootropic space, is cheap, is safe at standard doses, and doesn't cause tolerance. It also has meaningful limitations that most coverage ignores. Both sides are worth understanding.

The mechanism

Creatine's primary function is in the phosphocreatine energy system. Phosphocreatine acts as a rapid-release buffer for ATP — the cellular energy currency — in tissues with high and variable energy demand. When a cell depletes ATP faster than mitochondria can regenerate it, phosphocreatine donates a phosphate group to ADP to regenerate ATP quickly.

Skeletal muscle has high creatine content and high energy demand during exercise. This is why creatine became a sports supplement. But the brain also has high and variable energy demand — particularly during sustained cognitive work — and also expresses creatine kinase (the enzyme that uses phosphocreatine to regenerate ATP) throughout neural tissue.

Brain creatine content is influenced by dietary intake and supplementation. This is the key fact the cognitive argument rests on: creatine crosses the blood-brain barrier, brain levels can be measured and increased, and higher brain creatine levels are associated with faster ATP regeneration in neural tissue.

What the trials found — and the tension between them

The Rae et al. 2003 trial is the origin study. It established the cognitive case and is still widely cited.

p<0.0001 is a striking result for a nutritional supplement. The study became a reference point for nootropic discussions about creatine, and reasonably so.

But in 2023, the largest creatine cognition trial to date ran the same protocol — same dose, same duration, same cognitive tests — and found something different.

These are the same compound, same dose, same tests, same duration, twenty years apart. The first showed a clear effect. The second showed a borderline-to-absent effect. This is an honest tension in the literature that most creatine coverage smooths over.

The most defensible current position: creatine probably has a small positive effect on specific cognitive tasks, particularly those requiring working memory and processing speed. The effect is real enough to appear in Bayesian analysis of the larger trial. It's modest enough that the larger trial — better powered, better controlled — couldn't reach conventional significance on the primary outcomes.

The vegetarian question

The Rae 2003 study used exclusively vegetarian participants. The reasoning: vegetarians have lower dietary creatine intake (creatine is found primarily in meat and fish), therefore lower baseline brain creatine, therefore more room to respond to supplementation.

This is a mechanistically sound hypothesis. Lower baseline → larger supplementation effect is a reasonable prediction.

The Sandkühler 2023 trial included both vegetarians and omnivores and found no significant difference in response between groups. That's unexpected, and it complicates the "vegetarians benefit more" narrative.

One interpretation: baseline brain creatine may not vary as much by dietary status as expected, or the body's creatine synthesis capacity compensates for lower dietary intake more effectively than assumed. The mechanism is real; the dietary-status-as-predictor claim is less established than it appeared after the 2003 study.

The practical implication is uncertain. If you eat no meat or fish, the prior probability of having lower baseline brain creatine and responding to supplementation is probably higher. But it's not a guarantee, and the 2023 data suggests omnivores shouldn't dismiss creatine on the assumption they're already saturated.

What makes creatine unusual in the nootropic space

Three things distinguish it from most compounds discussed in this context.

No tolerance. Creatine doesn't work through receptor mechanisms that downregulate with chronic use. You're not blocking a receptor or stimulating a pathway that adapts. You're increasing substrate availability. The effect doesn't diminish over time. This is rare.

Long safety record. Creatine has been studied extensively in athletic populations for decades. At standard doses (3–5 g/day), no serious adverse effects have been identified in healthy adults. The most common side effect is gastrointestinal discomfort at higher doses, which typically resolves with dose reduction or switching to a slower-dissolving form.

Cheap and available. Creatine monohydrate costs roughly $0.10–0.20 per daily dose from reputable suppliers. It's not proprietary. There's no premium formulation offering better outcomes than generic monohydrate. This is unusual in a supplement market that charges $80/month for a multi-ingredient stack of underdosed compounds.

The honest bottom line

Creatine is probably effective for working memory and speed-dependent cognitive tasks, with a small effect size in well-rested healthy people. The effect may be larger in people with lower baseline brain creatine — vegetarians, vegans, older adults — though this hasn't been definitively established.

It's the least exciting nootropic argument: a cheap, safe, well-studied compound with a modest effect and no tolerance. No dramatic mechanism story, no counterculture appeal, no scarcity. Just a reasonable probability of a small improvement on the specific cognitive functions that often limit sustained knowledge work.

Given the evidence, the price, and the safety profile, the question for most people isn't whether to try creatine. It's why they haven't.